SMS Pharmaceuticals Limited (SMSPHARMA.BO)
INR 242.45
(2.08%)
INR 242.45
(2.08%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.06 Billion INR | 36.46% |
| 2022 | 5.19 Billion INR | 0.92% |
| 2021 | 5.15 Billion INR | -8.17% |
| 2020 | 5.6 Billion INR | 37.68% |
| 2019 | 4.07 Billion INR | -11.8% |
| 2018 | 4.61 Billion INR | 0.28% |
| 2017 | 4.6 Billion INR | 5.72% |
| 2016 | 4.35 Billion INR | -27.78% |
| 2015 | 6.03 Billion INR | 4.13% |
| 2014 | 5.79 Billion INR | 11.82% |
| 2013 | 5.18 Billion INR | 111.28% |
| 2012 | 2.45 Billion INR | 14.52% |
| 2011 | 2.14 Billion INR | -5.24% |
| 2010 | 2.25 Billion INR | 2.82% |
| 2009 | 2.19 Billion INR | -10.23% |
| 2008 | 2.44 Billion INR | 16.34% |
| 2007 | 2.1 Billion INR | 24.82% |
| 2006 | 1.68 Billion INR | 37.03% |
| 2005 | 1.23 Billion INR | 3.68% |
| 2004 | 1.18 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.64 Billion INR | -33.1% |
| 2023 Q1 | 1.35 Billion INR | -8.01% |
| 2023 Q4 | 2.45 Billion INR | 52.21% |
| 2023 FY | 7.09 Billion INR | 36.46% |
| 2023 Q3 | 1.61 Billion INR | -3.1% |
| 2023 Q2 | 1.66 Billion INR | 23.13% |
| 2022 Q4 | 1.47 Billion INR | -1.13% |
| 2022 FY | 5.19 Billion INR | 0.92% |
| 2022 Q1 | 643.88 Million INR | 14.86% |
| 2022 Q2 | 1.59 Billion INR | 147.61% |
| 2022 Q3 | 1.48 Billion INR | -6.67% |
| 2021 Q3 | 1.21 Billion INR | -30.59% |
| 2021 FY | 5.15 Billion INR | -8.17% |
| 2021 Q2 | 1.74 Billion INR | 7.08% |
| 2021 Q1 | 1.63 Billion INR | -3.42% |
| 2021 Q4 | 560.6 Million INR | -53.77% |
| 2020 Q1 | 1.12 Billion INR | 22.89% |
| 2020 Q2 | 1.3 Billion INR | 15.26% |
| 2020 FY | 5.6 Billion INR | 37.68% |
| 2020 Q3 | 1.48 Billion INR | 14.4% |
| 2020 Q4 | 1.68 Billion INR | 13.47% |
| 2019 Q3 | 804.48 Million INR | -31.76% |
| 2019 FY | 4.07 Billion INR | -11.8% |
| 2019 Q2 | 1.17 Billion INR | 0.65% |
| 2019 Q1 | 1.17 Billion INR | 16.41% |
| 2019 Q4 | 918.65 Million INR | 14.19% |
| 2018 Q1 | 1.25 Billion INR | 0.0% |
| 2018 FY | 4.61 Billion INR | 0.28% |
| 2018 Q4 | 1 Billion INR | -0.62% |
| 2018 Q3 | 1.01 Billion INR | -24.91% |
| 2018 Q2 | 1.34 Billion INR | 7.78% |
| 2017 FY | 4.6 Billion INR | 5.72% |
| 2016 FY | 4.35 Billion INR | -27.78% |
| 2016 Q1 | 1.45 Billion INR | -14.73% |
| 2016 Q2 | 1.78 Billion INR | 22.34% |
| 2015 Q2 | 1.52 Billion INR | 23.22% |
| 2015 FY | 6.03 Billion INR | 4.13% |
| 2015 Q4 | 1.71 Billion INR | 10.03% |
| 2015 Q3 | 1.55 Billion INR | 1.79% |
| 2015 Q1 | 1.23 Billion INR | -21.58% |
| 2014 Q3 | 1.48 Billion INR | 9.67% |
| 2014 Q2 | 1.35 Billion INR | -2.27% |
| 2014 FY | 5.79 Billion INR | 11.82% |
| 2014 Q1 | 1.38 Billion INR | -15.13% |
| 2014 Q4 | 1.58 Billion INR | 6.75% |
| 2013 Q1 | 899.88 Million INR | 55.68% |
| 2013 Q4 | 1.62 Billion INR | 18.35% |
| 2013 FY | 5.18 Billion INR | 111.28% |
| 2013 Q3 | 1.37 Billion INR | 6.67% |
| 2013 Q2 | 1.28 Billion INR | 43.28% |
| 2012 Q4 | 578.03 Million INR | -18.26% |
| 2012 Q1 | 538.38 Million INR | -16.34% |
| 2012 Q2 | 591.46 Million INR | 9.86% |
| 2012 FY | 2.45 Billion INR | 14.52% |
| 2012 Q3 | 707.11 Million INR | 19.55% |
| 2011 FY | 2.14 Billion INR | -5.24% |
| 2011 Q4 | 643.54 Million INR | 34.58% |
| 2011 Q3 | 478.19 Million INR | 0.0% |
| 2010 FY | 2.25 Billion INR | 2.82% |
| 2009 FY | 2.19 Billion INR | -10.23% |
| 2008 FY | 2.44 Billion INR | 16.34% |
| 2007 FY | 2.1 Billion INR | 24.82% |
| 2006 FY | 1.68 Billion INR | 37.03% |
| 2005 FY | 1.23 Billion INR | 3.68% |
| 2004 FY | 1.18 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Abbott India Limited | 58.48 Billion INR | 87.922% |
| Cipla Limited | 257.74 Billion INR | 97.259% |
| Gland Pharma Limited | 56.41 Billion INR | 87.478% |
| GlaxoSmithKline Pharmaceuticals Limited | 34.53 Billion INR | 79.545% |
| Kopran Limited | 6.14 Billion INR | -14.947% |
| Marksans Pharma Limited | 21.77 Billion INR | 67.555% |
| NGL Fine-Chem Limited | 3.38 Billion INR | -108.586% |
| Pfizer Limited | 21.93 Billion INR | 67.788% |
| Sanofi India Limited | 28.51 Billion INR | 75.222% |